Odonate Therapeutics (ODT)

Overall impact
B (65)

Commentary

Odonate Therapeutics is a strong overall performer. With a 'B' rating of 64.5 for overall impact (72nd percentile compared to all companies), Odonate Therapeutics ranks 352nd out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 348 others, and ahead of Grifols, Jazz Pharmaceuticals, Bluebird Bio and 230 others. On top material causes for Odonate Therapeutics's industry (Pharmaceuticals & Biotech), Odonate Therapeutics performs well in Access to Affordable Healthcare (87.1 score), Disease Eradication (96.4), Improved Mental Health (95.7) and 1 other cause where it received an 'A' score and performs poorly in Accountable Institutions (15.5 score), Reduced Green House Gas Emissions (34.8) and Accountable Institutions (5.8).
Impact
Cause ODT
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2013
Employees
137
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ny, United States
Share classes
ODT
Description
Odonate Therapeutics, Inc. is a pharmaceutical company that develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Material causes
Ethos considers the following causes material for Odonate Therapeutics, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.